SAB Biotherapeutics
SABS | NASDAQ
$3.00
+$0.04 (+1.35%)
At close: Nov 16, 2026, 4:00 PM ET
$3.00
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:10 PM ET
+1.35%
(1D)No price chart data available for 1D timeframe.
Rating
33
-1.5 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #706/1021 (Top 69%)
Key Statistics
Market Data
Market Cap $270.27M
1D Range
2.92 3.07
52W Range
2.49 4.59
Valuation (TTM)
PE -1.79
PB 1.28
EV/EBITDA -2.10
Valuation (NTM)
Forward PE N/A
Forward PEG -0.02
Price Target $12.00
Cash Flow
FCF Yield -27.4%
SBC Adj. FCF Yield -38.0%
SBC Impact -38.9%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -139.4% |
-90.3%
Dil EPS 3Y | 5Y 67.5% |
29.0%
FCF 3Y | 5Y -35.2% |
-28.6%
Returns
ROA -34.2%
ROE -40.0%
ROIC -38.4%
Financial Health
Net Cash
$104.05M
Current Ratio 7.28
Interest Coverage -451.87
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious dis...
Sector Healthcare
Industry Biotechnology
Employees 86
IPO Date Feb 9, 2021
Website www.sab.bio
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
4
Consensus
Buy
Price Target
$12.00
Upside
+300.00%
Buy (4)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove SABS